目录
更新日期:2022年9月21日
姓 名 周红升 性 别
民 族 汉族 导师层次 博士导师
技术职称 主任医师 导师类型 学术&专业型
最后学历 博士研究生毕业 最后学位 医学博士学位
行政职务 副主任 Email hanson_tcm@hotmail.com;zhs1@i.smu.edu.cn
工作单位 南方医科大学南方医院 邮政编码 510515
跨学科招生
跨学科招生专业1 临床遗传学 招生层次类型1 学术学位博导
跨学科招生专业2 招生层次类型2
个人简介

南方医科大学南方医院血液科

主任医师,亚专科主任,博士研究生导师

首届广州市珠江科技新星,首届广东省杰出青年医学人才

2007年毕业于华中科技大学同济医学院;

2013-2015年在MD Anderson癌症中心学习

中国免疫学会血液免疫分会        委员

中华医学会血液分会实验诊断学组    委员

广东省医学会血液病分会         常委兼秘书

广东省医学会血液青委会         副主任委员

广东省医学会血液病分会中西结合学组  副组长

广东欧美同学会青年分会          首届理事

主持国家基金4项,广东省基金2项,

在Leukemia,STM, BMT等杂志发表论文30余篇

研究领域

1.急性淋巴细胞白血病发病机制、代谢重编程与靶向治疗

2.抑癌基因成药的关键机制研究

3.CAR-T细胞疗法治疗血液肿瘤

个人成果

1. Zhou H, Mak PY, Mu H, Mak DH, Zeng Z, Cortes J, Liu Q, Andreeff M, Carter BZ. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia. 2017 Oct;31(10):2065-2074. doi: 10.1038/leu.2017.87. Epub 2017 Mar 21. PMID: 28321124; PMCID: PMC5628102.

2. Liang XJ, Song XY, Wu JL, Liu D, Lin BY, Zhou HS, Wang L. Advances in Multi-Omics Study of Prognostic Biomarkers of Diffuse Large B-Cell Lymphoma. Int J Biol Sci. 2022 Jan 9;18(4):1313-1327. doi: 10.7150/ijbs.67892. PMID: 35280688; PMCID: PMC8898353.

3. Tang B, Cai Z, Wang Z, Lin D, He X, Li Q, Liang X, Huang K, Zhou X, Lin R, Xu N, Fan Z, Huang F, Sun J, Liu X, Liu Q, Zhou H. Allogeneic hematopoietic stem cell transplantation overcome the poor prognosis of patients with IKZF1plus CD20-a very high-risk subtype in B-cell acute lymphoblastic leukemia. Bone Marrow Transplant. 2022 Sep 2. doi: 10.1038/s41409-022-01797-1. Epub ahead of print. PMID: 36056210.

4. Qi HZ, Xu J, Yang QQ, Lin R, Wang ZX, Zhao K, Wang Q, Zhou X, Fan ZP, Huang F, Xu N, Xuan L, Jin H, Sun J, Gale RP, Zhou HS, Liu QF. Effect of pediatric- versus adult-type chemotherapy regimens on outcomes of allogeneic hematopoietic stem cell transplants for adult T-cell acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplant. 2022 Aug 30. doi: 10.1038/s41409-022-01796-2. Epub ahead of print. PMID: 36042299.

5. He B, Wang Q, Liu X, Lu Z, Han J, Pan C, Carter BZ, Liu Q, Xu N, Zhou H. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Biomed Pharmacother. 2020 Sep;129:110390. doi: 10.1016/j.biopha.2020.110390. Epub 2020 Jun 17. PMID: 32563150.

6. Xiao J, Cai Z, Wang H, Li X, Zhou B, Liu Y, Wang Y, Xu P, Wang L, Wu D, Dou L, Zhou H, Xu Y. The Clinical Characteristics and Prognosis of AYA and Older Adult ETP-ALL/LBL: A Real-World Multicenter Study in China. Front Oncol. 2022 Jun 6;12:846573. doi: 10.3389/fonc.2022.846573. PMID: 35734596; PMCID: PMC9207171.

7. Zhou HS, Carter BZ, Andreeff M. Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang. Cancer Biol Med. 2016 Jun;13(2):248-59. doi: 10.20892/j.issn.2095-3941.2016.0023. PMID: 27458532; PMCID: PMC4944541.

8. Huang K, Dai M, Li Q, Liu N, Lin D, Wang Q, Zhou X, Wang Z, Gao Y, Jin H, Liu X, Liu Q, Zhou H. Early T-Cell Precursor Leukemia Has a Higher Risk of Induction-Related Infection among T-Cell Acute Lymphoblastic Leukemia in Adult. Mediators Inflamm. 2020 Dec 23;2020:8867760. doi: 10.1155/2020/8867760. PMID: 33424437; PMCID: PMC7775137.

9. Wang JD, Zhou HS, Tu XX, He Y, Liu QF, Liu Q, Long ZJ. Prediction of competing endogenous RNA coexpression network as prognostic markers in AML. Aging (Albany NY). 2019 May 31;11(10):3333-3347. doi: 10.18632/aging.101985. PMID: 31164492; PMCID: PMC6555472.

10. Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Huang X, Cortes J, Kantarjian H, Konopleva M, Andreeff M. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med. 2016 Sep 7;8(355):355ra117. doi: 10.1126/scitranslmed.aag1180. PMID: 27605552; PMCID: PMC5111086.